GLENN WONG, DO

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Leuprolide acetate (for depot suspension), 7.5 mg

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Instillation of anti-cancer drug into bladder

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Established patient office or other outpatient visit, 30-39 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Administration of additional new drug or substance into vein using push technique

Drawing of blood for a medical problem

Infusion into a vein for hydration, 31-60 minutes

Injection of drug or substance into vein

Injection, zoledronic acid, 1 mg

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of chemotherapy into vein, each additional hour

Cyclophosphamide, 100 mg

Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or

Collection of blood sample from implanted device

Injection, infliximab-abda, biosimilar, (renflexis), 10 mg

Injection of additional new drug or substance into vein

Injection of drug or substance under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Injection, pembrolizumab, 1 mg

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Injection, golimumab, 1 mg, for intravenous use

Infusion into a vein for hydration, each additional hour

Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

Injection, nivolumab, 1 mg

Injection, denosumab, 1 mg

Injection, epoetin alfa, (for non-esrd use), 1000 units

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units

Injection, carboplatin, 50 mg

Injection, methylprednisolone sodium succinate, up to 125 mg

Infusion, normal saline solution , 1000 cc

Bcg live intravesical instillation, 1 mg

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Unclassified drugs

Injection, fosaprepitant, 1 mg

Injection, diphenhydramine hcl, up to 50 mg

Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram

Injection, dexamethasone sodium phosphate, 1 mg

Injection, paclitaxel, 1 mg